TY - JOUR
T1 - Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion
AU - Abe, Hayato
AU - Mafune, Kenichi
AU - Minamimura, Keisuke
AU - Abe, Masashi
AU - Umemura, Akihisa
AU - Mirata, Tooru
PY - 2013/5
Y1 - 2013/5
N2 - The efficacy and safety of bevacizumab (BV), combined with infusional 5-fluorouracil/leucovorin (5-FU/LV) plus irinote-can (FOLFIRI) as the second-line treatment for metastatic colorectal cancer (mCRC) after resection of the primary lesion, have not been fully clarified. We examined clinical results of 35 patients on BV plus FOLFIRI at our hospital, and investigated the efficacy of BV plus FOLFIRI in mCRC patients who failed oxaliplatin-containing regimens (26 patients were treated with BV at a dose of 5 mg/kg, 3 patients with BV 10mg/kg, and 6 patients had BV Increased from 5mg/kg to 10mg/kg). The average frequency of BV plus FOLFIRI treatment was 13. 9 times, and the average length of treatment was 10.0 months. The overall response rate was 17.1% (CR 1 patient, PR 5 patients, SD 21 patients, PD 8 patients). The median PFS was 11.0 months for FOLFIRI plus BV after first-line chemotherapy, and the median 05 was 23.0 months. The adverse events were 77.1% (>Grade 3, 55.5%) and the BV-associated adverse event was grade 3 hypertension (2 patients). The FOLFIRI plus BV regimen is an active and well-tolerated second-line chemotherapy treatment for patients with mCRC after resection of the primary lesion.
AB - The efficacy and safety of bevacizumab (BV), combined with infusional 5-fluorouracil/leucovorin (5-FU/LV) plus irinote-can (FOLFIRI) as the second-line treatment for metastatic colorectal cancer (mCRC) after resection of the primary lesion, have not been fully clarified. We examined clinical results of 35 patients on BV plus FOLFIRI at our hospital, and investigated the efficacy of BV plus FOLFIRI in mCRC patients who failed oxaliplatin-containing regimens (26 patients were treated with BV at a dose of 5 mg/kg, 3 patients with BV 10mg/kg, and 6 patients had BV Increased from 5mg/kg to 10mg/kg). The average frequency of BV plus FOLFIRI treatment was 13. 9 times, and the average length of treatment was 10.0 months. The overall response rate was 17.1% (CR 1 patient, PR 5 patients, SD 21 patients, PD 8 patients). The median PFS was 11.0 months for FOLFIRI plus BV after first-line chemotherapy, and the median 05 was 23.0 months. The adverse events were 77.1% (>Grade 3, 55.5%) and the BV-associated adverse event was grade 3 hypertension (2 patients). The FOLFIRI plus BV regimen is an active and well-tolerated second-line chemotherapy treatment for patients with mCRC after resection of the primary lesion.
KW - FOLFIRI plus bevacizumab
KW - Metastatic colorectal cancer
KW - Second-line chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=84977262573&partnerID=8YFLogxK
M3 - Article
C2 - 23863581
AN - SCOPUS:84977262573
SN - 0385-0684
VL - 40
SP - 601
EP - 604
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 5
ER -